Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russian |
| Publicado em: |
IRBIS LLC
2019-01-01
|
| coleção: | Фармакоэкономика |
| Assuntos: | |
| Acesso em linha: | https://www.pharmacoeconomics.ru/jour/article/view/268 |